Considering the high proportion of HER2-positive patients among HR-negative patients (39.5%) in this study and the expected efficacy of adjuvant trastuzumab, it is reasonable to separate TN breast cancer from HR-negative breast cancer in planning treatment [27-29]. The gene discussed is ERBB2; the disease is breast carcinoma.